

Match Overview

1	Internet 180 words crawled on 27-Apr-2019 link.springer.com	4%
2	Internet 114 words crawled on 14-Sep-2010 www.biomedcentral.com	2%
3	Internet 99 words crawled on 11-Sep-2016 ajcn.nutrition.org	2%
4	Crossref 85 words Roxanne Vandenberg, Naveen P Khan, Jennifer L Est: ... "Linking Metabolic Disease With the PGC-1 α Gly482Ser	2%
5	Crossref 50 words Yan Zhang. "ASSOCIATION BETWEEN PPARGC1A GEN E POLYMORPHISMS AND CORONARY ARTERY DISE...	1%
6	Internet 33 words crawled on 07-Jan-2010 www.molnut.uni-kiel.de	1%
7	Crossref 26 words	

13
Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 64071

Manuscript Type: ORIGINAL ARTICLE

Basic Study

PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

PPARGC1A rs8192678 affects hepatic histological features and NASH.

Rui-Nan Zhang, Feng Shen, Qin Pan, Hai-Xia Cao, Guang-Yu Chen, Jian-Gao Fan

Peroxisome proliferator-activated receptor- γ coactivator-1 α rs8192

ALL

IMAGES

VIDEOS

5,230 Results

Any time ▾

Peroxisome proliferator-activated receptor γ coactivator ...

<https://www.ncbi.nlm.nih.gov/pubmed/29566941>

Peroxisome proliferator-activated receptor γ coactivator-1 α is a predictor of lymph node metastasis and poor prognosis in human colorectal cancer. Yun SH(1), Roh MS(2), Jeong JS(2), Park JI(3). Author information: (1)Department of Biochemistry, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-Gu, Busan 49201, Republic of Korea.

Cited by: 6

Author: Seong-Hoon Yun, Mee-Sook Roh, Jin-So...

Publish Year: 2018

Peroxisome proliferator-activated receptor γ coactivator ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/ace.12993>

Jul 10, 2019 - Peroxisome proliferator-activated receptor γ coactivator 1 α is a key regulator of mitochondrial biogenesis, dynamics, and function in young animals. Moreover, the effects of this transcriptional coactivator extend to other organelles and cell compartments, such as the unfolded protein response after exercise (Wu et al., 2011) and SR ...

Cited by: 3

Author: Jonathan F. Gill, Julien Delezie, Gesa Sa...

Publish Year: 2019

Peroxisome Proliferator-Activated Receptor- γ Coactivator ...

<https://pubmed.ncbi.nlm.nih.gov/30829051>

Aims: Vascular calcification is associated with cardiovascular death in patients with chronic kidney disease (CKD). Peroxisome proliferator-activated receptor- γ coactivator-1 α (PGC-1 α) plays an important role in various cardiovascular diseases. However, its role in vascular calcification remains unknown.

Cited by: 6

Author: Han Feng, Jin-Yu Wang, Bo Yu, Xin Cong...

Publish Year: 2019

Peroxisome Proliferator-Activated Receptor- γ Coactivator ...

<https://academic.oup.com/edrv/article/24/1/78/2424289> ▾

Abstract

I. Introduction

II. PGC-1 α Regulates Biologi...

III. Molecula



1. I.Introduction

2. II.PGC-1 α Regulates Biological Programs Linked to Energy Homeostasis

[Association between PPARGC1A polymorphisms and the ...](https://www.researchgate.net/publication/5264368...)

<https://www.researchgate.net/publication/5264368...>

Thus, this study was designed to evaluate the Gly482Ser polymorphism (rs8192678) within the PPARGC1A gene and its association with the increased risk of NAFLD in Iranian patients with type 2 ...

[Association between PPARGC1A polymorphisms and the ...](https://www.researchgate.net/publication/229024652...)

<https://www.researchgate.net/publication/229024652...>

The histological disease spectrum of NAFLD ranges from bland fatty liver (hepatic steatosis), to the concomitant presence of inflammation and ballooning which defines nonalcoholic steatohepatitis ...

[\(PDF\) Interactions of a PPARGC1A Variant and a PNPLA3 ...](https://www.researchgate.net/publication/299421688...)

<https://www.researchgate.net/publication/299421688...>

PDF | The patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant is associated with nonalcoholic fatty liver disease (NAFLD) and... | Find, read and cite all the research you need ...

[MERTK rs4374383 polymorphism affects the severity of ...](https://www.sciencedirect.com/science/article/pii/S0168827815007151)

<https://www.sciencedirect.com/science/article/pii/S0168827815007151>

Mar 01, 2016 - Introduction. Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide , , affecting about 20–30% of the general population .The clinical relevance of NAFLD arises from the evidence that NAFLD patients are at risk of progression to cirrhosis and its complications , presenting also a high rate of cancer and cardiovascular events compared to subjects

Search Tools

Turn off Hover Translation (关闭取词)

激活 Windows

转到“设置”以激活 Windows。

Association between PPARGC1A polymorphisms and the ...

<https://www.researchgate.net/publication/5264368...>

Thus, this study was designed to evaluate the Gly482Ser **polymorphism** (rs8192678) within the **PPARGC1A** gene and its association with the increased risk of NAFLD in Iranian **patients** with type 2 ...

Association between PPARGC1A polymorphisms and the ...

<https://www.researchgate.net/publication/229024652...>

The **histological disease** spectrum of NAFLD ranges from bland **fatty liver** (hepatic steatosis), to the concomitant presence of inflammation and ballooning which defines **nonalcoholic steatohepatitis** ...

(PDF) Interactions of a PPARGC1A Variant and a PNPLA3 ...

<https://www.researchgate.net/publication/299421688...>

PDF | The patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant is associated with **nonalcoholic fatty liver disease** (NAFLD) and... | Find, read and cite all the research you need ...

MERTK rs4374383 polymorphism affects the severity of ...

<https://www.sciencedirect.com/science/article/pii/S0168827815007151>

Mar 01, 2016 · Introduction. **Non-alcoholic fatty liver disease** (NAFLD) is a leading cause of chronic **liver disease** worldwide , , affecting about 20–30% of the general population .The clinical relevance of NAFLD arises from the evidence that NAFLD **patients** are at risk of progression to cirrhosis and its complications , , presenting also a high rate of cancer and cardiovascular events compared to subjects ...

Cited by: 84

Author: Salvatore Petta, Luca Valenti, Fabio Marra, ...

Publish Year: 2016

Glucokinase Regulatory Protein Gene Polymorphism Affects ...

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087523> ▾

Feb 03, 2014 · Introduction. **Non-alcoholic fatty liver disease** (NAFLD) is a frequent and growing cause of chronic **liver disease** , , affecting about 20%–30% of the general population worldwide .**Patients** with NAFLD, and especially those with **non-alcoholic steatohepatitis** (NASH), are at risk of progression to cirrhosis and its complications , , presenting also a high rate of cancer and cardiovascular events ...

Cited by: 100


Author: Salvatore Petta, Luca Miele, Elisabetta Bugi...

Publish Year: 2014

Insights into paediatric non-alcoholic fatty liver disease ...


Non-Alcoholic Fatty Liver Disease

Medical Condition



A condition in which fat accumulates in the liver in people who drink little or no alcohol.

 Very common (More than 3 million cases per year in US)

 Requires lab test or imaging

 Treatments can help manage condition, no known cure

 Can last several years or be lifelong

The cause of non-alcoholic fatty liver disease is not clearly understood. It is associated with obesity, insulin resistance, hyperglycemia, and high levels of fat in blood. The condition does not usually cause symptoms. In some cases, fatigue, enlarged liver, and pain in the upper right abdomen is seen. Non-alcoholic fatty liver disease has no specific treatment. It involves treating underlying conditions such as obesity.

Symptoms

Usually asymptomatic. Symptoms may include:

- Fatigue
- Enlarged liver
- Pain in the upper right abdomen